2. Anti-infection
  3. Bacterial
  4. Panobacumab

Panobacumab  (Synonyms: KBPA101)

Cat. No.: HY-P99214 Purity: 98.24%
SDS COA

Molarity Calculator

Panobacumab (KBPA101) is a fully human IgM/κ monoclonal antibody generated by immortalizing human B lymphocytes against the LPS O polysaccharide of serotype O11 of P. aeruginosa.

For research use only. We do not sell to patients.

CAS No. : 885053-97-4

Size Price Stock Quantity
1 mg USD 260 In-stock
5 mg USD 680 In-stock
10 mg USD 1080 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Panobacumab Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Panobacumab (KBPA101) is a fully human IgM/κ monoclonal antibody generated by immortalizing human B lymphocytes against the LPS O polysaccharide of serotype O11 of P. aeruginosa[1].

Isotype

IgM kappa
Species

Human
In Vitro

Panobacumab (KBPA101) strongly binds to 18 of 20 clinical O11 isolates, functional avidity of KBPA101 to O11 LPS determined by inhibition ELISA is 5.81×107 M-1± 2.8×107 M-1[1].
Panobacumab (KBPA101) (0.0001-100 ng/mL; 2 h) specifically mediates complement-dependent opsonophagocytosis of P. aeruginosa serotype O11 with an IC50 of 0.16 ng/mL[1].
Panobacumab (KBPA101) (0.1-10 ng/mL) shows direct complement-dependent killing of P. aeruginosa serotype O11 cells in a dose-dependent manner[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Panobacumab Related Antibodies
In Vivo

Panobacumab (KBPA101) (1-4 mg/kg; i.v.; once) protects mice from systemic infection with P. aeruginosa serotype O11 in a murine burn wound model[1].
Panobacumab (KBPA101) (0.005-0.4 mg/kg; i.v.; once) protects mice from local lung infection with P. aeruginosa serotype O11 in an acute lung infection model[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female NMRI mice, murine burn wound model[1]
Dosage: 1, 2, or 4 mg/kg
Administration: Intravenous injection, single dose
Result: Significantly reduced mortality compared to untreated control animals administered either immediately or 4 h postchallenge.
Animal Model: BALB/c mice, acute lung infection model[1]
Dosage: 0.005 to 0.4 mg/kg
Administration: Intravenous injection, single dose
Result: Led to rapid clearance of P. aeruginosa from the lung, completely cleared systemic P. aeruginosa from the spleen, whereas live bacteria were still present in untreated mice at 48 h postchallenge, showed milder macroscopic lung pathology at 6 and 24 h after infection.
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Panobacumab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • IgM-kappa
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Panobacumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Panobacumab885053-97-4KBPA101KBPA 101KBPA-101BacterialP. aeruginosaB lymphocytesLPS O polysaccharideserotype O11Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Panobacumab
Cat. No.:
HY-P99214
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.